Frontiers in Cell and Developmental Biology is an interdisciplinary journal that focuses on the fundamental biological processes of life.

Led by Field Chief Editor Prof Amanda Gay Fisher (University of Oxford, UK), this journal is indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, among others, and welcomes submissions on intracellular and extracellular dynamics.

The journal covers a wide spectrum of topics within cell and developmental biology including, but not limited to:

cancer cell biology
cell adhesion and migration
cell death and survival
cell growth and division
cellular biochemistry
developmental epigenetics
embryonic development
epigenomics and epigenetics
evolutionary developmental biology
membrane traffic and organelle dynamics
molecular and cellular pathology
molecular and cellular reproduction
morphogenesis and patterning
nuclear organization and dynamics
signaling
stem cell research.

In addition, Frontiers in Cell and Developmental Biology is interested in fundamental and translational research in molecular medicine and stem cell biology. The journal also welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being.

Manuscripts that focus solely on bioinformatics, computational analysis, or theoretical modeling without experimental validation are not suitable for publication in this journal. Additionally, studies that only report the therapeutic efficacy of certain compounds or treatments without providing insights into the underlying cellular and developmental biology mechanisms are not within the scope of this journal.

Frontiers in Cell and Developmental Biology is committed to advancing developments in the field by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.

Ethics Statement:

All manuscripts submitted to Cell and Developmental Biology that have been conducted in human subjects must conform with current regulations and the Declaration of Helsinki. Ethics committee approval and informed patient consent are required for studies involving human subjects. Ethics committee approval is also needed for studies involving animals. Phase I - Phase IV clinical trials submitted for publication in Frontiers in Cell and Developmental Biology must have been registered with an appropriate public trials registry at the time or before the first patient enrolment. The information on the clinical trial registration (Unique Identifier and URL) must be included in the abstract. Authors are required to disclose all apparent or potential conflicts of interest according to the ICMJE guidelines and those of Frontiers. 

Frontiers follows the guidelines and best practice recommendations published by the Committee on Publication Ethics (COPE). Authors should refer to the author guidelines for full details.

Submit your idea

Articles

Targeting alternative splicing in cancer immunotherapy

Frontiers in Cell and Developmental Biology

Impact